Tamoxifen: 1 risk of contralateral breast cancer in adjuvant setting; risk-benefit unclear when given as 1° prevention in Pts at T risk: I invasive breast cancer, butr DVT & uterine CA risk, and ? t in all-cause mortality (lancet 2002J60.817)
Raloxifene: i risk of invasive breast cancer & vertebral fx. 1 risk of stroke & DVT PE (rutrnqai 2006:355:125); - tamoxifen in prevention of breast cancer w 1 risk of DVT PE & cataracts, trend towards 1 uterine cancer (star.jama 2006:295:2727)
Aromatasc inhibitors under study
• BRCA1 2 carriers: several options, including intensified surveillance as described above
Prophylactic bilateral mastectomy (NEJM 2001:345 159) and bilateral sal pi ngo-oophorectomy (i risk of ovarian and breast cancer, nejm 2002:346:160*jama 2006:296.185) are effective.
Chemoprevention: limited data supports use of tamoxifen for risk reduction
Was this article helpful?